	(Based on PTO 01-08 version)								
	Substitute for form 1449/PTO			Complete if Known					
	Substitute for form 1449/FTO			Application Number	10/586,037				
	INFORMATION	1 DI	SCLOSURE	Filing Date	(Intl.) January 13, 2005				
	STATEMENT B	37	APPLICANT	First Named Inventor	Jeffrey L. SOUTHARD				
	OTATEMENT :		a i Liozari	Art Unit	Not Yet Assigned				
	(Use as many sh	eets a	s necessary)	Examiner Name	Not Yet Assigned				
She	et 1	of	3	Attorney Docket Number	560252000800				

	U.S. PATENT DOCUMENTS								
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
Initials*	No.	Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document					
	1.	US-4,720,483	01-19-1988	Jansz et al.					
	2.	US-4,764,378	08-16-1988	Keith et al.					
	3.	US-5,023,252	06-11-1991	Hseih					
	4.	US-5,728,396-A	03-17-1998	Peery et al.					
	5.	US-5,958,877-A	09-28-1999	Wimalawansa					
	6.	US-6,358,247-B1	03-19-2002	Altman et al.					
	7.	US-6,809,079-B2	10-26-2004	Southard et al.					
	8.	US-2008/0069865-A1	03-20-2008	Southard et al.					
	9.	US-2008/0097503-A1	04-24-2008	Creaven					

		FOREI	GN PATENT	DOCUMENTS		
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	
Initials*	No.	Country Code ³ -Number ⁴ -Kind Code ⁸ (if known)	MM-DD-YYYY	Applicant of Cited Document		Te
	10.	WO-93/23011-A1	11-25-1993	Minnesota Mining and Manufacturing Company		П
	11.	WO-96/30013-A1	10-03-1996	Minnesota Mining and Manufacturing Company		П
	12.	WO-03/059250-A2,A3	07-24-2003	Vasogenix Pharmaceuticals, Inc.		П
	13.	WO-2005/067890-A2,A3	07-28-2005	Vasogenix Pharmaceuticals, Inc.		П
	14.	WO-2005/070444-A2,A3,C1	08-04-2005	Vasogenix Pharmaceuticals, Inc.		
	15.	WO-2005/070445-A2,A3	08-04-2005	Vasogenix Pharmaceuticals, Inc.		
	16.	WO-2006/029320-A1	03-16-2006	Bayer Healthcare LLC		

Examiner	Date	
Signature	Considered	

EXAMINER Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through cluston if not in conformance and not considered include copy of the form with next communication to applicant. "Applicants' ampse catation designation number (coptions). "See Kinds Codes of Jacobs of Codes o

	(Based on PTO 01-08 Vers								
Г	Substitute for for	m 1440/DTO			Complete if Known				
	Substitute for for	m 1449/F1O			Application Number	10/586,037			
	INFORM	MATION	I DI	SCLOSURE	Filing Date	(Intl.) January 13, 2005			
	STATE	MENT	37 /	PPLICANT	First Named Inventor	Jeffrey L. SOUTHARD			
	0.7				Art Unit	Not Yet Assigned			
	(Use	e as many sh	eets as	necessary)	Examiner Name	Not Yet Assigned			
SI	neet	2	of	3	Attorney Docket Number	560252000800			

		NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.1	the item (book, magazine, journal, sena, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						
	17.	ANAND, I.S. et al. (January 1991). "Cardiovascular and Hormonal Effects of Calcitonin Gene-Related Peptide in Congestive Heart Failure," <i>J. Am. Coll. Cardiol.</i> 17(1):208-217.						
	18.	CHAI, W. et al. (February 15, 2006, e-pub. January 24, 2006). "The Role of Calcitonin Gene- Related Peptide (CGRP) in Ischemic Preconditioning in Isolated Rat Hearts," <i>European Journal of Pharmacology</i> 531(1-3):248-253.						
	19.	FLEISHER, D. et al. (1996). "Improved Oral Drug Delivery: Solubility Limitations Overcome by the Use of Prodrugs," <i>Advanced Drug Delivery Reviews</i> 19:115-130.						
	20.	GENNARI, C. et al. (1990). "Improved Cardiac Performance with Human Calcitonin Gene Related Peptide in Patients with Congestive Heart Failure," Cardiovascular Res. 24(3):239- 241.						
	21.	HAEGERSTRAND, A. et al. (May 1990). "Calcitonin Gene-Related Peptide Stimulates Proliferation of Human Endothelial Cells," <i>Proc. Natl. Acad. Sci. USA</i> 87(9):3299-3303.						
	22.	HUNT, S.A. et al. (2001). ACC/AHA Practice Guidelines: ACC/AHA Guidelines for the Evaluation and Management Chronic Heart Fallure in the Adult, American College of Cardiology and the American Heart Association, Inc., ed., pp. 1-56.						
	23.	International Search Report mailed on October 5, 2006, for PCT Application No. PCT/US2005/001224, filed on January 13, 2005, five pages.						
	24.	LU, EX. et al. (December 1996). "Calcitonin Gene-Related Peptide-Induced Preconditioning Improves Preservation with Cardioplegia," <i>Ann. Thorac. Surg.</i> 62(6):1748-1751.						
	25.	MERRIFIELD, R.B. (1963). "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide," Journal of the American Chemical Society 85:2149-2154.						
	26.	MERRIFIELD, R.B. (April 18, 1986). "Solid Phase Synthesis," Science 232(4748):341-347.	Г					
	27.	ROBINSON, R.P. et al. (January 5, 1996). "Discovery of the Hemifurmarate and (alpha-L- alamyloxy)methyl either as Prodrugs of an Antirheumatic Oxindole: Prodrugs for the Enolic OH Group," J. Med. Chem 39:10-18.						
	28.	SHEKHAR, Y.C. et al. (April 1, 1991). "Effects of Prolonged Infusion of Human Alpha Calcitonin Gene-Related Peptide on Hemodynamics, Renal Blood Flow and Hormone Levels in Congestive Heart Failure," Am. J. Cardiol. 67(8):						
	29.	SHIMIZU, K. et al. (December 1999). "Adrenomedullin Receptor Antagonism by Calcitonin Gene-Related Peptide (8-37) Inhibits Carolid Artery Neointimal Hyperplasia after Balloon Injury," Circulation Research 3(17):1199-1205.						
	30.	STEVENSON, R.N. et al. (December 1992), "Calcitonin Gene-Related Peptide: A Haemodynamic Study of a Novel Vascodilator in Patients with Severe Chronic Heart Failure," Intl. J. Carifol. 37(3):407-414.						
	31.	WIMALAWANSA, S. (October 1996). "Calcitonin Gene-Related Peptide and Its Receptors: Molecular Genetics, Physiology, Pathophysiology, and Therapeutic Potentials," Endocrine Reviews 17(5):533-585.						
	32.	WIMALAWANSA, S. (1997). "Amylin, Calcitonin Gene-Related Peptide, Calcitonin, and Adrenomedullin: A Peptide Superfamily," Critical Reviews in Neurobiology 11(2-3):167-239.						

	estitute for form 1449/PTO			Complete if Known		
Sut	ostitute for form 1449/PTO			Application Number	10/586,037	
111	VEORMATION	ı DI	SCLOSURE	Filing Date	(Intl.) January 13, 2005	
S	TATEMENT E	RV	APPLICANT	First Named Inventor	Jeffrey L. SOUTHARD	
"				Art Unit	Not Yet Assigned	
	(Use as many sh	eets a:	necessary)	Examiner Name	Not Yet Assigned	
Sheet	3	of	3	Attorney Docket Number	560252000800	

33.	WOLFRUM, S. et al. (April 15, 2005). "Calcitonin Gene Related Peptide Mediates Cardioprotection by Remote Preconditioning," Regulatory Peptides 127(1-3):217-224.	
34.	Written Opinion mailed on October 5, 2006, for PCT Application No. PCT/US2005/001224, filed on January 13, 2005, seven pages.	
35.	ZHOU, ZH. et al. (December 2001). "Improvement of Preservation with Cardioplegic Solution by Nitroglycerin-Induced Delayed Preconditioning is Mediated by Calcitonin Gene-Related Peptide," Int. J. Cardiol. 81(2-3):211-218.	

Examiner Signature	Date Considered	

^{*}EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{&#}x27;Applicant's unique citation designation number (optional). ^cApplicant is to place a check mark here if English language Translation is attached.